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Abstract
Background: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of
non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT).
Methods: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in
Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following:
1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of
the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed
the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary
lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative
chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70.
Results: The median overall survival (OS) of all 61 patients was 26 months (95 % CI: 17.5–34.5 months). The 2-year
and 5-year overall survival rates were 60.7 and 15.7 %, respectively. Stratified by oligostatus, the sync-oligometastases
group achieved a median OS of 18 months (95 % CI: 14.8–21.1 months) and a 5-year OS of 0 %, while the oligo-
recurrence group achieved a median OS of 41 months (95 % CI: 27.8–54.2 months) and a 5-year OS of 18.6 %.
On multivariate analysis, oligo-recurrence was the only significant independent factor related to a favorable
prognosis (hazard ratio: 0.253 (95 % CI: 0.082–0.043) (p = 0.025).
Conclusions: The presence of oligo-recurrence can predict a favorable prognosis of brain-only oligometastases in
patients with NSCLC treated with SRS or SRT.
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Background
Stage IV or recurrent stage IV patients have the shortest
overall survival. In non-small cell lung cancer (NSCLC),
the median overall survival is only 8 months, [1].
However, recent advances in molecular targeted drug
have not only improved the QOL of NSCLC patients,
but given them hope for survival. For example, patients
with EGFR mutant adenocarcinoma lung cancer (a type
of NSCLC) treated with EGFR-TKI have been reported
to achieve long-term survival while maintaining good
performance status [2]. EML4-ALK NSCLC patients
(adenocarcinoma only) treated with ALK-inhibitor have
also been shown to achieve long-term median survival
[2]. However, these findings were limited to patients
with driver oncogene mutations and driver-targeted
therapy for adenocarcinoma only. The results for squa-
mous cell carcinoma, large cell carcinoma, and other
types, as well as for adenocarcinoma not having driver
oncogene mutations, are much worse, as mentioned.
Furthermore, the personalized therapies for NSCLC
are no longer limited to molecular targeted drugs. In-
deed, there is a broad array of options beyond the mo-
lecular approach. Hellman, Wechselbaum, and Niibe
were the first to propose the concepts of oligometastases
and oligo-recurrence [3–5].
Oligometastases is defined as cases with 1 to 5 meta-
static lesions, mostly with an active primary lesion,
which are treated with local therapy (metastatic lesions)
and can achieve long-term survival [3].
Oligo-recurrence [4–7], on the other hand, is defined as
cases having 1–5 metastatic or recurrent lesions with con-
trolled primary lesions, which are treated by local therapy
such as surgery, stereotactic radiosurgery (SRS), stereotac-
tic body radiotherapy (SBRT), radiofrequency ablation
(RFA), and so on. These local therapies are strong and
minimally invasive. Thus, patients with oligo-recurrence
are treated for all gross tumors to maintain QOL and can
achieve long-term survival or, in some cases, even cure,
independent of their driver oncogene status. Thus, Palma
and Wechselbaum et al. emphasized the importance of
distinguishing between oligo-recurrence and oligometas-
tases precisely because oligo-recurrence carries such a
hopeful prognosis [8].
The current study investigates the importance of oligo-
recurrence comparing with sync-oligometastases in pa-
tients with brain-only NSCLC oligometastases. Non-small
lung cancer (NSCLC) patients with brain metastases is
not rare. However, sync-oligometastases (Brain-only me-
tastases NSCLC with active primary lesions were treated
with local therapy for primary lesions and SRS or SRT for
brain metastases) were very rare and as far as we know,
this is first clinical demonstration of treatment outcomes
of sync-oligometastases of NSCLC with brain-only metas-
tases. Furthermore, the current study also investigated an
analysis of the prognostic value of oligo-recurrence in
comparison with other previously reported factors.
Methods
Patients
The patients in the current study were treated with SRS
or SRT for brain-only NSCLC oligometastases at six
university hospitals or major cancer centers (Kitasato
University Hospital, Hokkaido University Hospital,
Shizuoka Cancer Center, Cancer and Infectious Dis-
eases Tokyo Metropolitan Komagome Hospital, Kyushu
University Hospital, and Tohoku University Hospital)
between 1996 and 2008. All institutional review boards
approved this study (Ethics Committee of Kitasato
University School of Medicine (B), Instittutional Review
Board of Hokkaido university Hospital for Clinical
Research, Ethics Committee of Shizuoka Cancer Center,
Ethical Committee of Tokyo Metropolitan Komagome
Hospital, Kyushu University Institutional Review Board
for Clinical Research, Ethics Committee of Tohoku
University Graduate School of Medicine). This study is
retrospective. Thus, informed consent of all patients
could not be acquired. Then, all institutions engaged in
this study announced this study on the web and/or
posters at the out-patients clinics at each hospital. If
targeted patients would not like to engage in this study,
they would convey their refusal to the researchers by
face to face, telephone or e-mail. However, no patients
proposed not to engage in this study.
Of the following criteria, eligible patients met 1), 2),
and 4) or 1), 3), and 4): 1) NSCLC with 1 to 4 brain me-
tastases detected by magnetic resonance imaging (MRI)
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treated with SRS or SRT; 2) control of the primary
lesions (thorax) at the time of SRS or SRT for brain me-
tastases (patients meeting this criterion formed the
oligo-recurrence group); 3) with SRS or SRT for brain
metastases, concomitant treatment for active primary
lesions (thorax) with curative surgery or curative SBRT
or curative chemoradiotherapy for primary lesions (sync-
oligometastases group, where “sync” indicates “synchron-
ous”) [7, 9]; 4) Karnofsky performance status (KPS) ≥70.
The exclusion criteria were: 1) NSCLC with five or more
brain metastases detected by MRI; and 2) NSCLC with 1
to 4 brain metastases for which surgery was previously
performed.
We compared the characteristics of oligo-recurrence
group and sync-oligometastases.
There were no statistically differences among these two
groups as following.
SRS and SRT treatments
Head rings were attached to the NSCLC patients and
fixed to the linear accelerator during SRS. The SRS
dose prescription was given at the tumor peripheral
margin (GTV + 1 mm = CTV, CTV + 1 mm = PTV)
(PTV peripheral dose).
NSCLC patients were treated with SRT while fixed to
the linear accelerator by head and face shells. The SRT
dose prescription was given at the tumor peripheral
margin (GTV + 1 mm =CTV, CTV + 2 mm = PTV)
(PTV peripheral dose). SRT was delivered in 4 to 5
fractions.
Treatments for thoracic lesions
Because patients in the oligo-recurrence group had
controlled primary lesions, no further treatments of
thoracic lesions were performed in this group until thor-
acic relapse. However, the sync-oligometastases group
had active thoracic lesions. Therefore, in this group, the
thoracic lesions were treated with curative surgery,
SBRT (cT1N0M1BRA) and concurrent chemoradiother-
apy, or with curative radiation therapy alone. SBRT was
mainly performed using 48 Gy/4 fractions (isocenter
dose) to the small primary lung cancer. Concurrent che-
moradiotherapy and curative radiation therapy alone
were mainly performed using 60 Gy/30 fractions (in all
cases, the spinal cord dose was under 40 Gy).
In general, the treatment strategy was to attempt to
target all gross malignant tumors.
Statistical analyses
Overall survival (OS), relapse-free survival (RFS), local
control of brain metastases (Brain-LC), cranial local
control (Cranial–LC), and local control of thoracic lesions
(Thoracic-LC) were calculated by the Kaplan-Meier
method.
Overall survival was calculated from the date of the
start of SRS or SRT for brain metastases, and an event
was defined as any death. Relapse-free survival (RFS)
was also calculated from the date of the start of SRS or
SRT for brain metastases, and the events were defined as
any site of relapse and any death. Local control of brain
metastases (Brain-LC) was calculated from the date of
the start of SRS or SRT for brain metastases, and the
event was defined as more than 25 % regrowth (diam-
eter) of brain metastases treated with SRS or SRT. Thus,
the emergence of new lesions in the brain was not
counted as an event when calculating Brain-LC. Cranial
local control (Cranial-LC) was also calculated from the
date of the start of SRS or SRT for brain metastases, and
the events were any type of cranial relapse, including at
the sites of SRS or SRT treatment, as well as the emer-
gence of new lesions in the brain regions not treated
with SRS or SRT. Local control for thoracic lesions
(Thoracic-LC) was calculated from the date of thoracic
lesion control by surgery or SBRT and concurrent che-
moradiotherapy. These dates were defined as the surgery
date, and the initiation date of SBRT or concurrent
chemoradiotherapy. An event was defined as any type of
intrathoracic relapse.
Univariate analysis of prognostic factors was performed
by the log-rank test for OS, Cranial-LC, Brain-LC, and
Thoracic-LC. The cut-off level of significance was defined
as p < 0.05.
For OS, Cranial-LC, Brain-LC, and Thoracic-LC,
multivariate analyses were also performed using Cox
proportional hazards models. The factors used in
these analyses were defined as those that were signifi-
cant (p < 0.05) or showed a nonsignificant trend to-
ward significance (p < 0.25) on univariate analysis and
clinically important factors such as RPA class, which
was previously reported to be a prognostic factor for
brain metastasis and is widely used for classification.
Results
A total of 61 patients in 6 major hospitals were registered.
The detailed characteristics of the patients are listed in
Table 1. Furthermore, the current study compared the
background of oligo-recurrence and sync-oligometastases.
There were no statistically differences among these two
groups, indicating in Table 2.
The median age was 64 years (range: 22–86 years).
There were 30 males and 31 females. Eleven patients
were in the sync-oligometastases group with active pri-
mary lesions (thorax). On the other hand, 50 patients
in the oligo-recurrence group had controlled primary
lesions (thorax). The number of patients with KPS
scores 70–80 and 90–100 were 5 and 56, respectively.
As for histopathology, 6, 48, and seven patients had
squamous cell carcinoma, adenocarcinoma, and other
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classified NSCLC, respectively. According to RPA class,
a previously proposed and widely used prognostic
factor for brain metastases [10], the 61 patients could
be classified into two groups: RPA class I (n = 26) and
RPA class II (n = 35). Because the current study in-
cluded only oligometastases, the number of RPA class
III patients was 0. Furthermore, Graded Prognostic
Assessment (GPA, newly proposed prognostic factor of
brain metastases) also could be classified into two
groups: Intermediate Prognosis Group (GPA score:
1.5–3.0, n = 50) and Favorable Prognosis Group (GPA
score: 3.5–4.0, n = 11) [9]. The number of lesions was
1–2 in 54 patients and 3–5 in seven patients. As for the
number of metastatic or recurrent lesions limited to
the brain, 42 were solitary, and 19 were 2–4. The me-
dian maximum size of metastatic or recurrent brain tu-
mors was 1.2 cm (range: 0.2–6.0 cm).
The treatment methods for brain metastases or recur-
rences were SRS in 45 patients and SRT in 16 patients.
The median prescription dose to PTV peripheral was
25 Gy (range: 10–36 Gy). External radiation therapy
was used concomitantly in nine patients. Nineteen
patients underwent chemotherapy. Neurologic function
was based on Professor Aoyama’s standard reported in
JAMA [11].
In brief, patients with no symptoms were assigned a
Grade of 0; patients with minor symptoms but who were
fully active without assistance were Grade 1; those with
moderate symptoms who were fully active but required
Table 1 Patients’ characteristics
Characteristic No. Percent










Sync-oligometastases (primary active) 11 18
Oligo-recurrence (primary controlled) 50 82
Histological status






Interval to initial brain recurrence, months
<12 29 48
≥12 32 52




Class I (aged <65 years; no active
extracranial diseases)
26 43




Score 0–1.0 (scoring based on Age, KPS,
ECM, No. of BM)
0 0
Score 1.5–2.0 5 8
Score 2.5–3.0 45 74
Score 3.5–4.0 11 18
Neurologic functiona
Grade 0 40 66
Grade 1 12 20
Grade 2 9 14
Grade 3 0 0
Grade 4 0 0
Maximum diameter of brain metastases, cm
Median (range) 1.2 (0.2–6.0)
Table 1 Patients’ characteristics (Continued)
Treatment method for brain tumor
SRS 45 74
SRT 16 26
Dose at the brain tumor margin, Gy





Treatment method for thoracic lesions
Surgery 43 70
Radiation therapy 18 30
Chemotherapy 19 31
Abbreviations: KPS Karnofsky performance status, RPA recursive partition
analysis, GPA graded prognostic assessment, SRS stereotactic radiosurgery, SRT
stereotactic radiotherapy, WBRT whole brain radiation therapy
aNeurologic function, grade 0 as no symptoms; grade 1 as minor symptoms,
fully active without assistance; grade 2 as moderate symptoms, fully active but
reguires assistance; grade 3 as moderate symptoms, less than fully active,
reguires assistance; grade 4 as severe symptoms, totally inactive
bThoracic stage classified according to the TNM classification of malignant
tumors version 6 (UICC, Union for International Cancer Control version 6
edition) not evaluating M stage
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assistance were Grade 2; those with moderate symptoms
but who were less than fully active and required assist-
ance were Grade 3; and patients with severe symptoms
who were totally inactive were Grade 4. In the current
study, 40 patients had Grade 0, 12 had Grade 1, 9 had
Grade 2, and no patients had Grade 3 or 4. As for
NSCLC staging excluding metastatic or recurrent lesions
(thoracic stage), 27 patients had stage I or II, and 34 had
stage III disease. Forty-three patients were treated with
surgery for thoracic lesions, and 18 patients were treated
with concurrent chemoradiotherapy or radiation therapy
alone.
Survival
The median overall survival of all 61 patients reached
26 months (95 % CI: 17.5–34.5 months). The 2-year and
5-year OS rates were 60.7 and 15.2 %, respectively (Fig. 1).
The results of univariate analysis of prognostic factors
for OS are shown in Table 3. Oligostatus (p = 0.001) and
the number of metastatic or recurrent lesions (p = 0.031)
were both significant prognostic factors. Oligostatus was
a powerful factor (Fig. 2); the sync-oligometastases group
achieved a median OS of 18 months (95 % CI: 14.8–
21.2 months) and a 5-year OS of 0 %. On the other hand,
the oligo-recurrence group achieved a median OS of
41 months (95 % CI: 27.8–54.2 months) and a 5-year OS
of 18.6 %.
However, RPA, the most frequently used standard for the
prediction of prognosis of patients with brain metastases,
achieved no significance for OS of NSCLC oligometastases.
RPA class I achieved a median OS of 30 months (95 % CI:
8.6–51.4 months), and RPA class II achieved a median OS
of 25 months (95 % CI: 10.6–39.4 months) (p = 0.319).
These results were almost identical (Fig. 3). Furthermore,
newly proposed prognostic classification, GPA also achieved
no significance for OS of NSCLC oligometastases. Inter-
mediate Prognosis Group of GPA scoring 1.5–3.0 achieved
a median OS of 26 months (95 % CI: 16.9–35.1 months),
and Favorable Prognostic Group of GPA scoring 3.5–4.0












<65 30 24 6 NS






1–2 54 45 9 NS




6 5 1 NS
adenocarcinoma
48 40 8
others 7 5 2
KPS score
70–80 5 5 0
90–100 56 45 11
interval to brain
recurrence, mo
<12 29 24 5 NS
>12 32 26 6
Neurologic function a
grade 0 40 31 7 NS
grade 1 12 10 2
grade2 9 9 0
grade3 0 0 0
grade4 0 0 0
Treatment method
for brain tumor
SRS 45 37 8 NS
SRT 16 13 3
WBRT 9 7 2 NS
Thoracic stage b
I–II 27 21 6 NS
III 34 29 5
Treatment method
for thoracic lesions
Table 2 Characteristics of Patients. Comparing oligo-recurrence
with sync-oligometastases (Continued)




Chemotherapy 19 12 7 NS
Abbreviations: KPS Karnofsky performance status, RPA recursive partition analysis,
SRS stereotactic radiosurgery, SRT stereotactic radiotherapy, WBRT whole brain
radiation therapy
aNerologic function, gradeO as no symptoms, grade 1 as minor symptoms:
fully active without assistance, grade2 as moderate symptomes; fully active
but requires assistance, grade3 as moderate symptoms: less than fully active,
requires assistance, grade4 as severe symptoms; totally inactive
bThoracic stage are classified according to TNM classification of malignant
tumors version 6 (UICC, Union for International Cancer Contorol version 6
edition) not evaluating M stage
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achieved a median OS 25 months (95 % CI: 0.0–
51.8 months) (p = 0.577) These results were almost identical
(Table 3). This was a very important finding of the current
analysis. In addition, a multivariate analysis was performed
using the factors that were found to be significant on uni-
variate analysis (oligostatus, the number of metastatic or re-
current lesions), those that showed a nonsignificant trend
toward significance (p < 0.25), and clinically important fac-
tors (RPA, histopathology, KPS score, interval to brain re-
currence (DFI), thoracic stage). The results of multivariate
analysis are shown in Table 4. Oligo-recurrence was ex-
tracted as the only independent prognostic factor (hazard
ratio: 0.253; 95 % CI: 0.082–0.043) (p = 0.025).
The median relapse-free survival reached 10 months
(95 % CI: 7.32–12.7 months), and the 2-year and the 5-
year RFS rates were 30.3 and 6.6 %, respectively.
Local control
Cranial-LC for all patients achieved a median of 30 months
(95%CI: 18.1–41.8 months), and 2-year Cranial-LC and 5-
year Cranial-LC rates were 68.1 and 10.7 %, respectively.
Univariate analysis of Cranial-LC was performed. There
were no significant factors for prognosis in Cranial-LC. A
Cox proportional hazards model multivariate analysis of
Cranial-LC was performed using factors with a nonsignifi-
cant trend toward significance and clinically important
factors (oligostatus, the number of brain metastases or
recurrences, and whole brain irradiation). Multivariate
analysis also found no significant factors.
Brain-LC of all patients achieved a median LC rate of
not reached, and 2-year Brain-LC and 5-year Brain-LC
rates were 80.3 and 66.3 %, respectively (Fig. 4). The
results of univariate analysis of Brain-LC are described
in Table 5. Histopathology (p = 0.017) and the maximum
tumor diameter (≥3 cm) (p = 0.002) were significant
prognostic factors. However, the relationship between
histopathology and the maximum tumor diameter
(<3 cm) was evaluated, and there was a correlation be-
tween histopathology and the maximum tumor diam-
eter. Nine of 11 tumors with squamous cell carcinoma
had a maximum tumor diameter <3 cm (81.8 %). On the
other hand, 68 of 69 adenocarcinomas had a maximum
tumor diameter <3 cm (98.6 %), and 6 of 9 NSCLCs with
other histology had a maximum tumor diameter < 3 cm
(66.7 %). Thus, adenocarcinoma tumors had a tendency
to be smaller than squamous cell carcinoma or other
NSCLC tumors. Histopathology was therefore excluded
from the multivariate analysis, and maximum tumor
diameter was included. The results of the Cox propor-
tional hazards model multivariate analysis are shown in
Table 6. The maximum tumor diameter showed a non-
significant trend toward significance (the maximum
tumor diameter was ≥3 cm; hazard ratio 3.81; 95 % CI:
0.95–15.3) (p = 0.059).
Thoracic-LC of all patients achieved a median LC rate
of not reached, and 2-year Thoracic-LC and 5-year
Thoracic-LC rates were 80.5 and 64.3 %, respectively.
Univariate analysis of Thoracic-LC was performed. Only
Fig. 1 Overall survival (OS) of all patients. The median OS is 26 months (95 % CI: 17.5–34.5 months). The 2-year OS and 5-year OS are 60.7 and
15.2 %, respectively. These results are favorable although all patients having metastases or recurrences
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oligostatus (p = 0.035) and use of systemic chemotherapy
(p = 0.022) were significant prognostic factors. However,
the relationship between oligostatus and systemic
chemotherapy was investigated, and a significant correl-
ation between these two factors was found. In the oligo-
recurrence group, 12 of 50 patients (24 %) underwent
systemic chemotherapy. On the other hand, in the
sync-oligometastases group, 7 of 11 patients (63.6 %)
underwent systemic chemotherapy. Thus, systemic
chemotherapy was excluded from the multivariate
analysis. The multivariate analysis thus included only
oligostatus and one clinically important factor (thor-
acic stage). Oligostatus was not an independent prog-
nostic factor (hazard ratio for oligo-recurrence: 0.405;
95 % CI: 0.121–1.353) (p = 0.142).
Discussion
Stage IV or recurrent stage IV lung cancer patients were
considered to be end-stage cancer patients until the
early 2000s. However, rapid progress was achieved in
clinical molecular targeted drugs of lung cancer in the
mid-2010s. It appears that some types of oncogenes
regulate lung cancer progression or suppression, such as
EGFR or ALK [12–14]. Based on these results, EGFR-
TKIs and ALK-inhibitors have been identified and man-
ufactured after FDA (US), EMA (Europe), and PMDA
(Japan) approval.
However, these patients are all oncogene-driven lung
cancer patients. Patients with lung cancer unrelated to
driver oncogene mutations still suffer from poor QOL
and low survival rates.
On the other hand, in the current study, oligo-
recurrent patients with NSCLC treated by SRS or SRT
achieved longer survival not depending on driver onco-
genes. The MST of OS in the oligo-recurrence group
Table 3 Univariate Analysis of Overall Survival




Age, median (range), y
<65 30 26 (17.2–34.8) 0.962
≥65 31 26 (8.3–43.8)
Sex
Male 30 32 (12.9–51.1) 0.489
Female 31 24 (13.8–34.2)
No. of metastatic/recurrent lesions
1–2 54 32 (18.0–46.0) 0.031
3–5 7 18 (10.3–25.7)
Oligostatus





Squamous cell carcinoma 6 32 (18.4–45.6) 0.233
Adenocarcinoma 48 19 (7.0–31.0)
Others 7 19 (8.7–29.3)
KPS score
70–80 5 24 (9.9–38.1) 0.169
90–100 56 32 (19.2–44.8)
Interval to brain recurrence, months
<12 29 19 (14.9–23.2) 0.081
≥12 32 41 (34.6–47.4)
No. of brain metastases
Single 42 26 (11.3–40.7) 0.817
2–4 19 26 (16.5–35.5)
RPA
Class I 26 30 (8.6–51.4) 0.319









Grade 0–1 40 26 (11.1–40.9) 0.945
Grade 2–4 21 26 (16.5–35.5)
Treatment method for brain tumor
SRS 45 26 (17.3–34.7) 0.792
SRT 16 25 (1.7–48.3)
WBRT
Yes 9 25 (11.1–38.9) 0.774
No 52 26 (12.0–40.0)
Thoracic stage b
Table 3 Univariate Analysis of Overall Survival (Continued)
I–II 27 25 (16.8–33.2) 0.199
III 34 37 (20.1–53.9)
Treatment method for thoracic lesions
Surgery 43 30 (20.2–39.8) 0.94
Radiation therapy 18 25 (3.2–46.8)
Chemotherapy
Yes 19 26 (24.1–27.9) 0.975
No 42 30 (9.0–51.0)
Abbreviations: KPS Karnofsky performance status, RPA recursive partition
analysis, GPR graded prognostic assessment, SRS stereotactic radiosurgery, SRT
stereotactic radiotherapy, WBRT whole brain radiation therapy
aNeurologic function, grade 0 as no symptoms; grade 1 as minor symptoms,
fully active without assistance; grade 2 as moderate symptoms, fully active but
requires assistance; grade 3 as moderate symptoms, less than fully active,
requires assistance; grade 4 as severe symptoms, totally inactive
bThoracic stage classified according to the TNM classification of malignant
tumors version 6 (UICC, Union for International Cancer Control version 6
edition) not evaluating M stage
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Fig. 3 Overall survival (OS) stratified by RPA class. RPA is not a significant prognostic factor for brain metastases, despite its wide use
for this purpose
Fig. 2 Overall survival (OS) stratified by oligostatus. The oligo-recurrence group has a significantly better OS than the oligometastases group. The
oligo-recurrence group has an MST of 41 months independent of driver oncogenes
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reached 41 months (95 % CI: 27.8–54.2 months). More-
over, these patients could achieve a “cure”. The 2-year
and 5-year OS rates were 60.7 and 15.2 %, respectively,
for the oligo-recurrence group. Molecular-targeted drugs
could achieve longer survival for specific NSCLC pa-
tients. However, these drugs could not achieve a “cure”
due to the acquired resistance of tumor cells. This point
is very important.
Ashworth et al. recently reported from their meta-
analysis that the most important prognostic factor was
metachronous oligometastases in patients with NSCLC
oligometastases [15]. However, these results must be
evaluated very cautiously. The use of metachronous
oligometastases is not appropriate in the area of oligome-
tastases. Metachronous oligometastases brought similar
good results to oligo-recurrence. However, metachronous
oligometastases include concomitant relapse of primary
and metastatic lesions, although oligo-recurrence excludes
this type of relapse.
Concomitant relapse of primary and metastatic lesions
is a state similar to that of sync oligometastases, rather
than one resembling oligo-recurrence. Thus, for this
type of relapse we cannot achieve good OS while main-
taining good QOL. Second, in the medical scientific
literature, the concept of oligo-recurrence was proposed
before that of metachronous oligometastases. Thus,
Fig. 4 Brain local control rate (Brain-LC) of all patients. The 2-year and 5-year Brain-LC rates are 80.3 and 66.3 %, respectively. These results are
comparable to previous studies
Table 4 Multivariate Analysis of Overall Survival
Variable Hazard ratio (95 % Cl) p value
No. of metastatic/recurrent lesions (1–2) 0.453 (0.152–1.240) 0.155
Oligo-recurrence group 0.253 (0.082–0.843) 0.035
Adenocarcinoma 0.496 (0.211–1.164) 0.107
KPS score (90–100) 0.330 (0.120–1.066) 0.064
Interval to brain recurrence, ≥12 months 1.158 (0.509–2.636) 0.726
RPA (class I) 1.319 (0.556–3.071) 0.521
Thoracic stage a (I–II) 1.544 (0.777–3.066) 0.215
Abbreviations: KPS Karnofsky performance status, RPA recursive partition analysis
aThoracic stage is classified according to the TNM classification of malignant tumors version 6 (UICC, Union for International Cancer Control version 6 edition) not
evaluating M stage
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oligo-recurrence was the original concept related to oli-
gometastases with controlled primary lesions. Accord-
ingly, the meta-analysis of Ashworth should be revised
using the appropriate key term of oligo-recurrence.
The multivariate analysis using a Cox proportional
hazards model in the current study concluded that
oligo-recurrence was the best prognostic factor in brain-
only oligometastases in patients with NSCLC (hazard ra-
tio: 0.253; 95 % CI: 0.082–0.043) (p = 0.025) (Table 4).
The major contribution of this analysis thus goes be-
yond the above-described finding that oligo-recurrence
was the only independent prognostic factor. Until now,
the standard prognostic factor for brain metastases has
been RPA class or GPA [9, 10]. However, Fig. 3 and
Table 2 shows that neither RPA nor GPA were signifi-
cant prognostic factors for oligometastases of NSCLC
(RPA, p = 0.319) (GPA, p = 0.577). The multivariate ana-
lysis also confirmed that RPA was not a prognostic fac-
tor for oligometastases of NSCLC (hazard ratio: 1.31; 95
% CI: 0.557–3.05) (p = 0.54).
The 2-year and 5-year Cranial-LC rates were 68.1 and
10.7 %, respectively. The median control time of Cranial-
LC was 30 months (95 % CI: 18.1–41.8 months).
Increasing Cranial-LC requires whole brain radiation ther-
apy combined with SRS or SRT. However, neurocognitive
function decreases when patients undergo whole brain ra-
diation therapy [16]. Thus, recently, when intracranial re-
lapse occurred, we elected to perform SRS or SRT
repeatedly whenever possible. In the current study, there-
fore, only nine patients underwent whole brain radiation
therapy. Thus, the results of Cranial-LC are not good.
The Brain-LC rates of all patients achieved the median
LC rate of not reached, and the 2-year Brain-LC and 5-
year Brain-LC rates were 80.3 and 66.3 %, respectively.
These results were almost the same as the findings re-
ported previously [11]. The present study thus confirms
that SRS or SRT for small brain metastases achieves
good treatment results as an alternative to surgery (log-
rank test, maximum tumor diameter brain tumors
<3 cm achieve 2-year Brain-LC of 82.8 %, p = 0.002;
multivariate analysis, ≥3 cm, hazard ratio 3.81 (95 % CI:
0.95–15.3), p = 0.059 (marginally significant correlation
of Brain-LC)).
Thoracic-LC findings in the current study were as fol-
lows. The 2-year Thoracic-LC and 5-year Thoracic-LC
rates were 80.5 and 64.3 %, respectively. These results
were reasonable in the current study setting.
There are some limitations in the current study. First,
this is retrospective study. The number of registered pa-
tients is limited to 61 subjects. There are some differ-
ence in the treatment methods even among six high
volume institutions.
Conclusions
In conclusion, oligo-recurrence can only predict a favor-
able prognosis of brain-only oligometastases in patients
with non-small cell lung cancer treated with SRS or
SRT. To the best of our knowledge, this is the first clin-
ical demonstration that oligo-recurrence is the most im-
portant favorable prognostic factor for oligometastases
in NSCLC. We are currently conducting a prospective
study of oligometastases to confirm that oligo-
recurrence is the most important favorable prognostic
factor in NSCLC and other cancers.
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Table 6 Multivariate Analysis of Local Control of Brain Tumc
Variable Hazard ratio (95 % Cl) p value
Size of brain tumor (≥3 cm) 3.81 (0.95–15.3) 0.057
SRS 0.632 (0.425–4.10) 0.828
Abbreviations: SRS stereotactic radiosurgery









11 53.7 % (11 months) 0.017
Adenocarcinoma 69 85.50 %
Others 9 55.60 %
Size of brain tumor
<3 cm 83 82.80 % 0.002
≥3 cm 6 44.40 %
Treatment method for brain tumor
SRS 66 84.90 % 0.098
SRT 23 60.0 % (23 months)
WBRT
Yes 13 84.60 % 0.701
No 76 81.30 %
Chemotherapy
Yes 29 79.40 % 0.725
No 60 73.90 %
Abbreviations: SRS stereotactic radiosurgery, SRT stereotactic radiotherapy,
WBRT whole brain radiation therapy
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